- Portugal brings deadly forest fires under control
- Postecoglou defends Solanke after slow start to Spurs career
- US nuclear plant Three Mile Island to reopen to power Microsoft
- Arteta urges Arsenal to take next step in Man City showdown
- Stock markets fall after Fed-fuelled rally
- Top Hezbollah commander 'killed' in Israel strike
- Poland charges Russian over attack on Navalny ally: prosecutors
- Man City have rest 'advantage' in Arsenal showdown: Guardiola
- Maresca has 'no doubt' in Jackson as Chelsea's number nine
- EU chief announces 35 bn euro loan plan for Ukraine before winter
- From TikTok to Hollywood, the irresistible rise of Italy's Khaby Lame
- Verstappen punished for swearing in Singapore press conference
- Sri Lanka lead by 202 in first New Zealand Test
- Brook 'not too fussed' by England's batting in heavy Australia loss
- India's Ashwin 'happy' to embrace pressure
- A modern 'Trojan Horse': two days of mayhem in Lebanon
- Third of Burundi mpox cases in children under five: UN
- Man Utd appoint Foster + Partners to develop Old Trafford 'masterplan'
- Israel-Hezbollah exchanges intensify on Lebanon border
- French mayor sorry for 'no one died' remark over mass rape trial
- Mohamed Al-Fayed, outsider shunned by British high society
- Lawyers say 'monster' late Harrods owner abused dozens of women
- India in box seat after Bumrah takes four against Bangladesh
- Taiwan retains death penalty but limits use to 'exceptional' cases
- Ferrari's Leclerc sets early pace in Singapore ahead of Norris
- 10 years into Huthi rule, some Yemenis count the cost
- France poised to finally get new govt
- Kompany, Alonso call for action on player workload amid strike talks
- Liverpool goalkeeper Alisson doubtful for Bournemouth clash
- Bumrah takes four as India bowl out Bangladesh for 149
- Sri Lanka 134-1 to take upper hand in first New Zealand Test
- Bayern's Kompany calls for game cap for players amid strike talks
- Christie's expands Hong Kong footprint in hope of art market 'pickup'
- Sultry screen legend Sophia Loren turns 90
- Cambodian opposition figure in court on incitement charge
- Bumrah takes three wickets to have Bangladesh in trouble at 112-8
- Kimchi threat as heatwave drives up South Korea cabbage prices
- UK economic data delivers fresh blow to new govt
- China to 'gradually resume' seafood imports from Japan after Fukushima ban
- India minister blames dam release for flooding
- O'Rourke strikes early for Kiwis as Sri Lanka trail by three
- Deep takes two as Bangladesh totter in reply to India's 376
- Israel pounds Lebanon's Hezbollah after device blasts
- Revolution or mirage? Controversy surrounds new Alzheimer's drugs
- Ashwin's 113 powers India to 376 in Bangladesh Test
- Biden opens home to 'Quad' leaders for farewell summit
- Sally Rooney returns with 30-something questions
- Wallabies sense 'massive' chance to upset All Blacks
- Taiwan questions two in probe into Hezbollah pagers
- Viral Korean Olympic shooter scores first acting role as assassin
RBGPF | 5.79% | 60.5 | $ | |
CMSC | -0.12% | 25.09 | $ | |
CMSD | 0.08% | 25.03 | $ | |
SCS | -2.62% | 12.97 | $ | |
RIO | -1.42% | 64.27 | $ | |
RELX | -0.14% | 48.065 | $ | |
BCC | -1.45% | 142.62 | $ | |
NGG | 0.65% | 69.28 | $ | |
JRI | -0.07% | 13.39 | $ | |
GSK | -1.25% | 41.105 | $ | |
BCE | -0.72% | 34.94 | $ | |
AZN | -0.41% | 78.58 | $ | |
RYCEF | 0.14% | 6.96 | $ | |
BTI | -0.22% | 37.489 | $ | |
VOD | -0.45% | 10.015 | $ | |
BP | -0.86% | 32.48 | $ |
EU watchdog approves vaccine targeting Omicron sub-variants
The EU's medicines watchdog on Monday approved a vaccine specifically targeting the new and contagious types of the Omicron variant amid fears of a new wave of Covid-19 winter infections.
The so-called "bivalent" jab, made by Pfizer/BioNTech, is directed at the highly infectious BA.4 and BA.5 types of the variant and is the first of its kind to be approved within the 27-nation bloc.
"This recommendation will further extend the arsenal of available vaccines to protect people against Covid-19 as the pandemic continues and new waves of infections are anticipated in the cold season," the European Medicines Agency (EMA) said.
The vaccine also targets "the original strain of SARS-CoV-2" and comes 11 days after the Amsterdam-based drug watchdog approved vaccines by Pfizer and Moderna against the Omicron BA.1 variant.
The latest shot is aimed at people over 12 and who have already received at least one primary vaccination against the coronavirus, and it is an adaptive version of Pfizer's original Comirnaty vaccine.
European nations have been keen to rush through the new generation of jabs so they can start booster campaigns ahead of a feared Covid surge in the latter part of this year.
The latest vaccines "better match the circulating variants of SARS-CoV-2 and are expected to provide broader protection against different variants," the EMA said.
"Prompt assessment of the available data on these adapted vaccines will enable their timely deployment in the autumn vaccination campaigns," it added.
The EMA's recommendation -- which will now be sent to the European Commission for a final decision -- was specifically based on clinical data from Pfizer's vaccines aimed at the original virus and the Omicron BA.1 variant.
- New wave feared -
"Apart from containing mRNA matching different, but closely related, Omicron sub-variants, Comirnaty Original/Omicron BA.4-5 and Comirnaty Original/Omicron BA.1 have the same composition," the EMA said.
Pfizer's vaccine works on the principle of tiny molecules carrying instructions for the human body to temporarily produce spike proteins similar to those found on the coronavirus -- and which it uses to enter the body's cells.
The body's immune system recognises the spike protein as foreign and activates natural defences against them.
When a person then comes in contact with the real virus, the body's immune system will also recognise and attack it.
The United States authorised its first anti-Omicron vaccines late last month, approving Pfizer and Moderna jabs for the BA.4 and BA.5 strains.
Britain authorised the Moderna vaccine for the BA.1 type in mid-August.
While the original vaccines, approved nearly two years ago provided some protection against newer coronavirus variants, the race had been on to come out with a newer group of vaccines that also target the milder but more infectious Omicron strains.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sub-lineages have dominated throughout 2022.
The BA.4 and BA.5 types have in particular helped to drive a wave of new cases of the disease in Europe and the United States in recent months.
All Omicron variants tend to have a milder disease course as they settle less in the lungs and more in the upper nasal passages, causing symptoms like fever, tiredness and loss of smell.
jhe/rox
D.Sawyer--AMWN